Group emphasizes need to identify type 2 diabetes subtypes, their responses to different therapies
TUESDAY, April 6 (HealthDay News) -- Expanded analysis of existing data sources and the development of new research studies that include a greater focus on identifying type 2 diabetes subtypes and their responses to different therapies are important to help individualize therapies for the disease, according to a review published in the April issue of the Journal of Clinical Endocrinology & Metabolism.
Robert J. Smith, M.D., of the Alpert Medical School of Brown University in Providence, R.I., and colleagues made up a 29-member international working group with specialization in diabetes epidemiology, physiology, genetics, clinical trials, and clinical care that participated in formal presentations and discussions during a conference held April 16 to 17, 2009. A writing group then prepared recommendations for individualized treatment of type 2 diabetes patients.
The authors write that identification of genetic markers such as Kir6.2 mutations and the genes responsible for several forms of maturity onset diabetes of the young have established precedents that link specifically effective therapies to defined diabetes subtypes. In addition, potential opportunities for individualized therapy now exist with the recent rise in identified polygenic factors related to type 2 diabetes and further knowledge of the pathogenesis of diabetes. They recommend extended analysis of existing data and data sources, expansion of existing data registries or development of new ones, development of new clinical trials and new technologies, and an expansion of basic research.
"We recommend expanded analysis of existing data sources and the development of new basic and clinical research studies, including a greater focus on identifying type 2 diabetes subtypes, their response to different therapies, and quantitation of cost-effectiveness," the authors write.
The recommendations are based on findings from a conference that received financial support from Novo Nordisk.
Full Text (subscription or payment may be required)